Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of cadonilimab in recurrent or metastatic vulvar cancer
CTR20232307Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Vulval carcinoma, sponsored by Akeso, Inc.. Started Aug 2023; status: completed.
02
Drugs
cadonilimab
03
Conditions
Vulval carcinoma
Beyond the preview
Go deeper on CTR20232307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232307.